We therefore used our optimised 3D GSC TTFields delivery protocol in a matched MGMT+ (a genetic/cellular marker which confers a poorer clinical TMZ response [1]) glioblastoma tumour core (typically resected) and edge (typically residual) model [27,28] to test these multi-modal regimens and provide proof-of-concept data around our preclinical methodology (Figure 5). The gene discussed is MGMT; the disease is glioblastoma.